On Thursday, AbbVie stock got an upgrade to its Relative Strength (RS) Rating, from 68 to 71.
When you're researching the best stocks to buy and watch, be sure to pay attention to relative price strength.
IBD's unique RS Rating tracks technical performance by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains tend to have an RS Rating of at least 80 as they launch their biggest runs. See if AbbVie stock can continue to show renewed price strength and hit that benchmark.
Looking For Winning Stocks? Try This Simple Routine
Is AbbVie Stock A Buy?
AbbVie stock is working on a consolidation with a 168.11 buy point. See if the drug maker stock can break out in volume at least 40% higher than normal.
Although earnings and sales growth came in at -14% and -5%, respectively, in the latest report, that marked acceleration for both the top and bottom lines.
AbbVie stock earns the No. 9 rank among its peers in the Medical-Ethical Drugs industry group. Novartis ADR and Zoetis are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
